|
1 Bierings M, Nachman JB, Zwaan CM. Stem cell transplantation in pediatric leukemia and myelodysplasia: State of the art and current challenges. Curr Stem Cell Res Ther, 2007, 2(1)：53–63.
|
|
2 Krishnamurti L, Abel S, Maiers M, et al. Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathies. Bone Marrow Transplant, 2003, 31(7)：547–550.
|
|
3 Schrier SL, Angelucci E. New strategies in the treatment of the thalassemias. Annu Rev Med, 2005, 56：157–171.
|
|
4 Ho VT, Revta C, Richardson PG. Hepatic veno–occlusive disease after hematopoietic stem cell transplantation：Update on defibrotide and other current investigational therapies. Bone Marrow Transplant，2008, 41(3)：229–237.
|
|
5 da Fonseca MA, Hong C. An overview of chronic oral graft–vs–host disease following pediatric hematopoietic stem cell transplantation. Pediatr Dent, 2008, 30(2)：98–104.
|
|
6 Kato K, Khaled Y, Mineishi S. Reduced–intensity stem cell transplantation for hematological malignancies：Current status and the future. Curr Stem Cell Res Ther, 2007, 2(2)：149–162.
|
|
7 Luo M, Bazargan N, Griffith DP, et al. Metabolic effects of enteral versus parenteral alanyl–glutamine dipeptide administration in critically ill patients receiving enteral feeding：A pilot study. Clin Nutr, 2008, 27(2)：297–306.
|
|
8 Fuentes–Orozco C, Cervantes–Guevara G, Mucino–Hernández I, et al. L–alanyl–L–glutamine–supplemented parenteral nutrition decreases infectious morbidity rate in patients with severe acute pancreatitis. JPEN J Parenter Enteral Nutr, 2008, 32(4)：403–411.
|
|
9 Duska F, Fric M, Waldauf P, et al. Frequent intravenous pulses of growth hormone together with glutamine supplementation in prolonged critical illness after multiple trauma：Effects on nitrogen balance, insulin resistance, and substrate oxidation. Crit Care Med, 2008, 36(6)：1707–1713.
|
|
10 Bunpo P, Murray B, Cundiff J, et al. Alanyl–glutamine consumption modifies the suppressive effect of L–asparaginase on lymphocyte populations in mice. J Nutr, 2008, 138(2)：338–343.
|
|
11 Savy GK. Glutamine supplementation. Heal the gut, help the patient. J Infus Nurs, 2002, 25(1)：65–69.
|
|
12 Mertes N, Schulzki C, Goeters C, et al. Cost containment through L– alanyl– L–glutamine supplemented total parenteral nutrition after major abdominal surgery：A prospective randomized double–blind controlled study. Clin Nutr, 2000, 19(6)：395–401.
|
|
13 Déchelotte P, Hasselmann M, Cynober L, et al. L–alanyl–L–glutamine dipeptide–supplemented total parenteral nutrition reduces infectious complications and glucose intolerance in critically ill patients: The French controlled, randomized, double–blind, multicenter study. Crit Care Med, 2006, 34(3)：598–604.
|
|
14 Satoh J, Tsujikawa T, Fujiyama Y, et al. Enteral alanyl–glutamine supplement promotes intestinal adaptation in rats. Int J Mol Med, 2003, 12(4)：615–620.
|
|
15 Schmucker DL.Intestinal mucosal immunosenescence in rats. Exp Gerontol, 2002, 37(2–3)：197–203.
|
|
16 Braga–Neto MB, Warren CA, Oriá RB, et al. Alanyl–glutamine and glutamine supplementation improves 5–fluorouracil–induced intestinal epithelium damage in vitro. Dig Dis Sci, 2008, 53(10)：2687–2696.
|
|
17 Luo M, Fernandez–Estivariz C, Jones DP, et al. Depletion of plasma antioxidants in surgical intensive care unit patients requiring parenteral feeding：Effects of parenteral nutrition with or without alanyl–glutamine dipeptide supplementation. Nutrition, 2008, 24(1)：37–44.
|
|
18 Lima NL, Soares AM, Mota RM, et al. Wasting and intestinal barrier function in children taking alanyl–glutamine–supplemented enteral formula. J Pediatr Gastroenterol Nutr, 2007, 44(3)：365–374.
|
|
19 Wu K, Wang BX, Wang XP. The protective effect of glutamine on intestinal immune function in acute nerotizing pancreatitis in rat. Chin J Gastroenterol Hepat, 2001, 10：39–41.[吴恺，王冰娴，王兴鹏. 谷氨酰胺对急性坏死性胰腺炎大鼠肠道黏膜局部免疫功能的保护作用. 胃肠病学和肝病学杂志，2001, 10：39–41.]
|
|
20 Carneiro BA, Fujii J, Brito GA, et al. Caspase and bid involvement in Clostridium difficile toxin A–induced apoptosis and modulation of toxin A effects by glutamine and alanyl–glutamine in vivo and in vitro. Infect Immun, 2006，74(1)：81–87.
|
|
21 Zhang X, Wang WZ, Li MB, et al. Effects of dipeptiven enriched parenteral nutrition on bacterial translocation and mucosa membrane structure of the transplanted small intestine in rats. J Fourth Military Med Univ, 2002, 23：1989–1992.[张溪，王为忠，李孟彬，等．力肽强化肠外营养对小肠移植大鼠肠黏膜结构及肠道细菌移位的影响. 第四军医大学学报，2002, 23：1989–1992.]
|
|
22 Ockenga J, Borchert K, Stüber E, et al. Glutamine–enriched total parenteral nutrition in patients with inflammatory bowel disease. Eur J Clin Nutr, 2005, 59(11)：1302–1309.
|
|
23 Brito GA, Carneiro–Filho B, Oriá RB, et al. Clostridium difficile toxin A induces intestinal epithelial cell apoptosis and damage: Role of Gln and Ala–Gln in toxin A effects. Dig Dis Sci, 2005, 50(7)：1271–1278.
|
|
24 Kudsk KA, Wu Y, Fukatsu K, et al. Glutamine–enriched total parenteral nutrition maintains intestinal interleukin–4 and mucosal immunoglobulin A levels. JPEN J Parenter Enteral Nutr, 2000, 24：270–275.
|
|
25 Wan XY, Bi LY, Zhang YL. Protective effect of glutamine on rats with pseudomonas pneumonia. Chin J Inten Med, 2006, 45(12)：1004–1007.[万献尧，毕丽岩，张永利. 谷氨酰胺对铜绿假单胞菌所致肺部感染大鼠的防护作用. 中华内科杂志，2006, 45(12)：1004–1007.]
|
|
26 Zhang XQ, Li JS, Shi X, et al. Experimental study of effects of glutamine–enriched TPN on acute rejection of small bowel transplantation. J Shandong Univ, 2001, 39：531–536.[张小桥，黎介寿，施鑫，等. 谷氨酰胺强化TPN对小肠移植急性排斥反应影响的实验研究. 山东医科大学学报，2001, 39：531–536.]
|
|
27 Zhou HS, Hu JM, Zhang DH, et al. Effects of glutamine supplementation on Th1/Th2 cytokines level in patients undergoing hematopoietic stem cell transplantation. Chin J Clin Nutrit, 2006, 14(6)：365–368.[周红升，胡金梅，张东华，等. 谷氨酰胺双肽对造血干细胞移植后患者血清Th1/Th2类细胞因子水平的影响. 中国临床营养杂志，2006, 14(6)：365–368.]
|
|
28 Mapara MY, Leng C, Kim YM, et al. Expression of chemokines in GVHD target organs is influenced by conditioning and genetic factors and amplified by GVHR. Biol Blood Marrow Transplant, 2006, 12(6)：623–634.
|
|
29 Johansson JE, Ekman T. Gut toxicity during hemopoietic stem cell transplantation may predict acute graft–versus–host disease severity in patients. Dig Dis Sci, 2007, 52(9)：2340–2345.
|
|
30 Stelljes M, Hermann S, Albring J, et al. Clinical molecular imaging in intestinal graft–versus–host disease：Mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography. Blood, 2008, 111(5)：2909–2018.
|